Ionis Pharmaceuticals IONS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $943.71M+33.8% | $705.14M-10.5% | $787.65M+34.1% | $587.37M-27.5% | ||
| $15.91M+41.8% | $11.22M+22.8% | $9.13M-35.3% | $14.12M+30.2% | ||
| $927.8M+33.7% | $693.92M-10.9% | $778.51M+35.8% | $573.25M-28.3% | ||
| 98.3%-0.1pp | 98.4%-0.4pp | 98.8%+1.2pp | 97.6%-1.1pp | ||
| $915.62M+1.6% | $901.53M+0.2% | $899.63M— | —— | ||
| $393.87M+47.3% | $267.47M+15.0% | $232.62M+54.8% | $150.3M-19.3% | ||
| $1.33B+12.3% | $1.18B+3.4% | $1.14B+14.4% | $997.56M+18.7% | ||
| -$381.69M+19.7% | -$475.08M-34.3% | -$353.73M+13.8% | -$410.19M-1,259% | ||
| -40.4%+26.9pp | -67.4%-22.5pp | -44.9%+24.9pp | -69.8%-66.1pp | ||
| $17.26M+1.6% | $16.99M+34.2% | $12.66M+55.9% | $8.12M-13.1% | ||
| -$15.36M-1,254% | $1.33M-90.6% | $14.1M+291% | -$7.4M+24.2% | ||
| -$379.6M+17.5% | -$460.07M-37.8% | -$333.97M-29.5% | -$257.99M— | ||
| $1.79M+129% | -$6.17M-119% | $32.32M+175% | $11.74M— | ||
| -$381.39M+16.0% | -$453.9M-23.9% | -$366.29M-35.8% | -$269.72M-843% | ||
| -40.4%+24.0pp | -64.4%-17.9pp | -46.5%-0.6pp | -45.9%-42.4pp | ||
| -$2.44+19.7% | -$3.04-18.8% | -$2.56-34.7% | -$1.90-400% | ||
| -$369.24M+20.3% | -$463.13M-35.9% | -$340.88M+13.4% | -$393.45M-3,087% | ||
| -39.1%+26.6pp | -65.7%-22.4pp | -43.3%+23.7pp | -67%-65.5pp | ||
| -$381.69M+19.7% | -$475.08M-34.3% | -$353.73M+13.8% | -$410.19M-1,259% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ionis Pharmaceuticals's revenue?
- Ionis Pharmaceuticals (IONS) generated $1.1B in revenue over the trailing twelve months, up 47.5% year over year.
- Is Ionis Pharmaceuticals profitable?
- Ionis Pharmaceuticals is not currently profitable: it reported a net loss of $327.0M over the trailing twelve months, a -30.9% net margin.
- What are Ionis Pharmaceuticals's profit margins?
- Gross margin is 98.4% and operating margin is -33.3%, with a -30.9% net margin.
- What is Ionis Pharmaceuticals's earnings per share?
- Ionis Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.07.
- Where does Ionis Pharmaceuticals's income statement data come from?
- Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
